Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BST2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BST2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View BST2 Products |
| Gene Delivery | BST2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View BST2 Products |
| Benchmark Ab | Anti-BST2 (Sequence of Clinical Benchmarks) Recombinant positive control. |
View BST2 Products |
| Validator | BST2 siRNA Set For knockdown verification. |
View BST2 Products |
| Related Target A | BCMA Synergistic target for Multiple Myeloma combinations |
View BCMA Products |
| Related Target B | CD38 Established biomarker for plasma cell malignancies |
View CD38 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Epitope Validation | HEK293 Expressed (Native Glycosylation) for accurate type II transmembrane protein folding |
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live BST2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BST2 (CD317/Tetherin) therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs and CAR-T cell therapies. As a type II transmembrane protein highly overexpressed in multiple myeloma and various solid tumors, BST2 presents an ideal tumor-associated antigen. As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecific combinations to overcome tumor escape mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Early-stage Biopharma | Multiple Myeloma, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Academic / Biotech | Relapsed/Refractory MM | Binding Affinity (Need native glycosylated antigen) |
| Bispecific | Oncology Innovators | Immunotherapy | Heterodimer Validation (Need Cross-reactive Abs) |